JC Xu, M.D., Ph.D., is the Chief Scientific Officer of Adagene. Dr. Xu has more than 20 years of experience in oncology drug discovery and development and more than 4 years of experience in business development, strategy, and operations in the U.S. biopharmaceutical industry.
Prior to joining Adagene, Dr. Xu was head of R&ED China Strategy at Celgene (now Bristol Myers Squibb). Prior to that, Dr. Xu was Director of Strategy & Operations at Celgene Quanticel Research and Director of Biology at Quanticel Pharmaceuticals. She was instrumental in the successful acquisition of Quanticel by Celgene. Prior to Quanticel, Dr. Xu worked in leadership roles at a number of biopharmaceutical companies, both large and small, including Pfizer, Amgen, and Corixa.
Dr. Xu received her M.D. from Beijing Medical University (now Peking University Health Science Center) and her Ph.D. in immunology from University of Alabama at Birmingham. She completed her post-doctoral training at DNAX Research Institute (now Merck Palo Alto). She is an inventor of more than 120 issued and pending patents and has published more than 50 articles in peer-reviewed journals.